Evidence map›Paper›PMID 37098914›Full record

ArticleAntimicrobial agents and chemotherapy2023

Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.

Julie Bertrand, Aurélie Barrail-Tran, Lucie Fayette, Rada Savic, Cécile Goujard, Elina Teicher, Caroline Barau, Alain Pruvost, Anne-Marie Taburet, France Mentré and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Julie BertrandUMR 1137, IAME, INSERM, Université Paris Cité, Paris, France.ORCID 0000-0002-6568-1041
Aurélie Barrail-TranAP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin-Bicêtre, France.ORCID 0000-0002-6053-6275
Lucie FayetteUMR 1137, IAME, INSERM, Université Paris Cité, Paris, France.
Rada SavicDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-3143-5579
Cécile GoujardAP-HP, Hôpital Bicêtre, Service de médecine interne et d'immunologie clinique, Le Kremlin-Bicêtre, France.
Elina TeicherAP-HP, Hôpital Bicêtre, Service de médecine interne et d'immunologie clinique, Le Kremlin-Bicêtre, France.
Caroline BarauAP-HP, Hôpital Henri Mondor, Plateforme de Ressources Biologiques, Créteil, France.
Alain PruvostDépartement Médicaments et Technologies pour la Santé, SPI, CEA, INRAE, Université Paris Saclay, Paris, France.
Anne-Marie TaburetAP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin-Bicêtre, France.
France MentréUMR 1137, IAME, INSERM, Université Paris Cité, Paris, France.
Céline VerstuyftCESP, Team Epidémiologie Clinique, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, France.
Inserm · FRUniversité Paris-Sud · FRCentre de recherche en Epidémiologie et Santé des Populations · FRAssistance Publique – Hôpitaux de Paris · FRUniversity of California, San Francisco · USCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tenofovir (TFV) and emtricitabine (FTC) are part of the recommended highly active antiretroviral therapy (ART). Both molecules show a large interindividual pharmacokinetic (PK) variability. Here, we modeled the concentrations of plasma TFV and FTC and their intracellular metabolites (TFV diphosphate [TFV-DP] and FTC triphosphate [FTC-TP]) collected after 4 and 24 weeks of treatment in 34 patients from the ANRS 134-COPHAR 3 trial. These patients received daily (QD) atazanavir (300 mg), ritonavir (100 mg), and a fixed-dose combination of coformulated TFV disoproxil fumarate (300 mg) and FTC (200 mg). Dosing history was collected using a medication event monitoring system. A three-compartment model with absorption delay (

Indexed as

Anti-HIV AgentsHIV InfectionsEmtricitabineHumansPolyphosphatesTenofovirAnti-HIV AgentsEmtricitabinePolyphosphatesTenofovirtriphosphoric acidantiretroviralHIVmixed-effect modelsnonlinear modelspharmacogeneticspharmacokinetics

Identifiers

PMID37098914
PMCPMC10190280
OpenAlexW4367047815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.